Search

Your search keyword '"Cartron, G."' showing total 551 results
Start Over Author "Cartron, G."
551 results on '"Cartron, G."'

1. MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

Author

Kater, AP, Harrup, R, Kipps, TJ, Eichhorst, B, Owen, CJ, Assouline, S, Lamanna, N, Robak, T, Serna, JDL, Jaeger, U, Cartron, G, Montillo, M, Mellink, C, Chyla, B, Thadani‐Mulero, M, Lefebure, M, Jiang, Y, Millen, R, Boyer, M, and Seymour, JF

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphoma, Cancer, Clinical Research, Lymphatic Research, Rare Diseases, Hematology, 6.2 Cellular and gene therapies, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Published
2023

5. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Author

Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., da Silva, M. Gomes, Bouabdallah, R., Salles, G., and Bachy, E.

Published
2018
Full Text
View/download PDF

6. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Author

Marouf, A., primary, Chaubard, S., additional, Michot, J., additional, Liévin, R., additional, Rossignol, J., additional, Golfier, C., additional, Allangba, O., additional, Philippe, L., additional, Tessoulin, B., additional, Chauchet, A., additional, Deau, B., additional, Oberic, L., additional, Vargaftig, J., additional, Moignet, A., additional, Clavert, A., additional, Dulery, R., additional, Brisou, G., additional, Tardy, S., additional, Fataccioli, V., additional, Houot, R., additional, Casasnovas, R., additional, Thieblemont, C., additional, Ghesquières, H., additional, Carras, S., additional, Le Gouill, S., additional, Cartron, G., additional, Marabelle, A., additional, Tournilhac, O., additional, Damaj, G., additional, Gaulard, P., additional, De Leval, L., additional, Lemonnier, F., additional, Bachy, E., additional, Hermine, O., additional, Couronné, L., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

7. Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study

Author

Tournilhac, O., primary, Altmann, B., additional, Friedrichs, B., additional, Bouabdallah, K., additional, Cartron, G., additional, Nickelsen, M., additional, Wulf, G., additional, Leclerc, M., additional, Vilatte, A., additional, Turlure, P., additional, Sanhès, L., additional, Houot, R., additional, Roussel, M., additional, de Leval, L., additional, Rosenwald, A., additional, Gaulard, P., additional, Dreger, P., additional, Glass, B., additional, Latière, C., additional, Damaj, G., additional, Lenz, G., additional, Reimer, P., additional, Banos, A., additional, Bilger, K., additional, Durot, E., additional, Sibon, D., additional, Wagner, E., additional, Nguyen, S., additional, Trümper, L., additional, Ziepert, M., additional, and Schmitz, N., additional

Published
2023
Full Text
View/download PDF

8. A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Author

Mozas, P., primary, Ammar, R. Ould, additional, Chartier, L., additional, Nastoupil, L., additional, Bachy, E., additional, Bezsera, S. M., additional, Barnes, J., additional, Bijou, F., additional, Goy, A., additional, Zerazhi, H., additional, Cartron, G., additional, Ojeda‐Uribe, M., additional, Choquet, S., additional, Joly, B., additional, Cheminant, M., additional, García‐Sancho, A. Martín, additional, Eradat, H., additional, Gressin, R., additional, Abrisqueta, P., additional, Parcelier, A., additional, Salazar, M. J. Rodríguez, additional, Bonnet, C., additional, Crump, M., additional, López‐Guillermo, A., additional, and Morschhauser, F., additional

Published
2023
Full Text
View/download PDF

9. COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Author

Hutchings, M., primary, Dickinson, M., additional, Carlo‐Stella, C., additional, Morschhauser, F., additional, Bosch, F., additional, Gritti, G., additional, Townsend, W., additional, Bartlett, N. L., additional, Cartron, G., additional, Ghesquieres, H., additional, Houot, R., additional, Walter, H., additional, Offner, F., additional, Christiansen, A., additional, Dimier, N., additional, Jamois, C., additional, Harrop, E., additional, Herter, S., additional, Hölzlwimmer, G., additional, Keelara, A., additional, Korfi, K., additional, Luong, J., additional, Mueller, C., additional, Mycroft, S., additional, Whayman, M., additional, Prieto, I., additional, Rukina, D., additional, and Lechner, K., additional

Published
2023
Full Text
View/download PDF

10. TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Author

Morschhauser, F., primary, Dahiya, S., additional, Palomba, M. L., additional, Garcia‐Sancho, A. M., additional, Ortega, J. L. Reguera, additional, Kuruvilla, J., additional, Jager, U., additional, Cartron, G., additional, Izutsu, K., additional, Dreyling, M., additional, Kahl, B., additional, Ghesquieres, H., additional, Ardeshna, K., additional, Goto, H., additional, Barbui, A. M., additional, Abramson, J. S., additional, Borchmann, P., additional, Fleury, I., additional, Mielke, S., additional, Farazi, T., additional, Fasan, O., additional, Lymp, J., additional, Vedal, M., additional, Nishii, R., additional, Avilion, A., additional, Papuga, J., additional, and Nastoupil, L. J., additional

Published
2023
Full Text
View/download PDF

12. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Author

Houot, R., primary, Bachy, E., additional, Cartron, G., additional, Gros, F., additional, Morschhauser, F., additional, Oberic, L., additional, Gastinne, T., additional, Feugier, P., additional, Dulery, R., additional, Thieblemont, C., additional, Joris, M., additional, Jardin, F., additional, Choquet, S., additional, Casasnovas, O., additional, Brisou, G., additional, Cheminant, M., additional, Bay, J., additional, Gutierrez, F. Llamas, additional, Menard, C., additional, Tarte, K., additional, Delfau, M., additional, Itti, E., additional, Bailly, C., additional, Al Tabaa, Y., additional, Laurent, C., additional, and Lemonnier, F., additional

Published
2023
Full Text
View/download PDF

17. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

Author

SESQUES, P., primary, DI BLASI, R., additional, LE GOUILL, S., additional, CARTRON, G., additional, MANSON, G., additional, BEAUVAIS, D., additional, LE BRAS, F., additional, GROS, F. X., additional, CHOQUET, S., additional, BORIES, P., additional, RUBIO, M. T., additional, CASASNOVAS, R. O., additional, BOUNAIX, L., additional, MOHTY, M., additional, JORIS, M., additional, ABRAHAM, J., additional, CASTILLA LLORENTE, C., additional, LOSCHI, M., additional, CARRAS, S., additional, CHAUCHET, A., additional, DRIEU LA ROCHELLE, L., additional, ZERBIT, J., additional, HERMINE, O., additional, GUIDEZ, S., additional, GASTINNE, T., additional, TUDESQ, J. J., additional, FOGARTY, P., additional, BROUSSAIS, F., additional, MORSCHHAUSER, F., additional, HOUOT, R., additional, THIEBLEMONT, C., additional, and BACHY, E., additional

Published
2022
Full Text
View/download PDF

18. S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS

Author

Dickinson, M., primary, Carlo-Stella, C., additional, Morschhauser, F., additional, Bachy, E., additional, Corradini, P., additional, Iacoboni, G., additional, Khan, C., additional, Wróbel, T., additional, Offner, F., additional, Trněný, M., additional, Wu, S.-J., additional, Cartron, G., additional, Hertzberg, M., additional, Sureda, A., additional, Perez-Callejo, D., additional, Lundberg, L., additional, Relf, J., additional, Clark, E., additional, Humphrey, K., additional, and Hutchings, M., additional

Published
2022
Full Text
View/download PDF

19. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.

Author

Cartron, G., primary, Bachy, E., additional, Tilly, H., additional, Daguindau, N., additional, Pica, G.-M., additional, Bijou, F., additional, Mounier, C., additional, Clavert, A. M., additional, Damaj, G. L., additional, Slama, B., additional, Casasnovas, O., additional, Houot, R., additional, Bouabdallah, K., additional, Sibon, D., additional, Fitoussi, O., additional, Morineau, N., additional, Herbaux, C., additional, Gastinne, T., additional, Fornecker, L.-M., additional, Haioun, C., additional, Launay, V., additional, Araujo, C., additional, Benbrahim, O., additional, Sanhes, L., additional, Gressin, R., additional, Gonzalez, H., additional, Morschhauser, F., additional, Xerri, L., additional, Tarte, K., additional, and Pranger, D., additional

Published
2022
Full Text
View/download PDF

20. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY

Author

Bachy, E., primary, Le Gouill, S., additional, Sesques, P., additional, Di Blasi, R., additional, Guillaume, M., additional, Cartron, G., additional, Beauvais, D., additional, Roulin, L., additional, Gros, F. X., additional, Rubio, M. T., additional, Bories, P., additional, Bay, J. O., additional, Castilla Llorente, C., additional, Choquet, S., additional, Casasnovas, R.-O., additional, Mothy, M., additional, Guidez, S., additional, Joris, M., additional, Loschi, M., additional, Carras, S., additional, Abraham, J., additional, Chauchet, A., additional, Drieu La Rochelle, L., additional, Zerbit, J., additional, Hermine, O., additional, Gastinne, T., additional, Tudesq, J. J., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, Houot, R., additional, and Morschhauser, F., additional

Published
2022
Full Text
View/download PDF

21. S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

Author

Townsend, W., primary, Hiddemann, W., additional, Buske, C., additional, Cartron, G., additional, Cunningham, D., additional, Dyer, M. J., additional, Gribben, J., additional, Phillips, E., additional, Dreyling, M., additional, Seymour, J. F., additional, Grigg, A., additional, Lin, T.-Y., additional, Hong, X.-N., additional, Kingbiel, D., additional, Nielsen, T. G., additional, Knapp, A., additional, Herold, M., additional, and Marcus, R., additional

Published
2022
Full Text
View/download PDF

23. Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper

Author

Bailly, S, Cartron, G, Chaganti, S, Cordoba, R, Corradini, P, Dull, J, Ferrarini, I, Osborne, W, Rosenwald, A, Sancho, JM, Tilly, H, Van den Neste, E, Viardot, A, and Visco, C

Subjects
relapsed, refractory, CD19, non-Hodgkin lymphoma, diffuse large B-cell lymphoma
Abstract

The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.

Published
2022

24. GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY.

Author

Dickinson, M., Carlo‐Stella, C., Morschhauser, F., Falchi, L., Bachy, E., Cartron, G., Khan, C., Tani, M., Martinez‐Lopez, J., Bartlett, N., Salar, A., Brody, J., Leppä, S., Mulvihill, E., Lundberg, L., Relf, J., Xie, Y., Bottos, A., Humphrey, K., and Hutchings, M.

Subjects
LYMPHOMAS, ADVISORY boards
Abstract

B Introduction: b Glofitamab is a CD20xCD3 bispecific antibody delivered in a fixed course of 12 three-weekly cycles. GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.

Author

Loyaux, R., Sako, N., Quang, V. Tran, Bachy, E., Morschhauser, F., Cartron, G., Gressin, R., Daguindau, N., Le Gouill, S., Wolfromm, A., Bouabdallah, K., Ysebaert, L., Casasnovas, O., Robe, C., Delfau, M., Dupuis, J., De Leval, L., Gaulard, P., Sloma, I., and Lemonnier, F.

Subjects
T-cell lymphoma
Abstract

Demonstration of I TET2 i and I DNMT3A i mutations in B cells, myeloid cells, or hematopoietic progenitor cells have suggested that TFHL can emerge from clonal hematopoiesis (CH) in a multi-step process. Follicular helper T-cell lymphoma (TFHL) results from the oncogenic transformation of a TFH cell, driven by mutations in genes involved in epigenetic regulation ( I TET2 i , I DNMT3A, IDH2 i ) and T-cell signaling ( I RHOA i ). Meanwhile, bulk BM cells from 29 patients were sequenced with the same NGS panel and then compared to the mutations found in cfDNA (31 patients) and tumor biopsies (28 patients). [Extracted from the article]

Published
2023
Full Text
View/download PDF

26. Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.

Author

Vic, S., Thibert, J., Bachy, E., Cartron, G., Gastinne, T., Morschhauser, F., Le Bras, F., Bouabdallah, K., Despas, F., Bay, J., Rubio, M., Mohty, M., Casasnovas, O., Choquet, S., Castilla‐Llorente, C., Guidez, S., Loschi, M., Guffroy, B., Carras, S., and La Rochelle, L. Drieu

Subjects
T cells, CD19 antigen, ERYTHROCYTES, LYMPHOMAS, CYTOKINE release syndrome
Abstract

Transfusion needs may impact patients' quality of life and CAR T-cells efficacy through transfusion-related immunomodulation. Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. B Introduction: b Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or CAR T-cells. [Extracted from the article]

Published
2023
Full Text
View/download PDF

27. PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA.

Author

Sesques, P., Di blasi, R., Legouill, S., Cartron, G., Beauvais, D., Le Bras, F., Gros, F., Choquet, S., Bories, P., Rubio, M., Casasnovas, R., Bay, J., Mohty, M., Joris, M., Abraham, J., Llorente, C. Castilla, Loschi, M., Carras, S., Chauchet, A., and Gyan, E.

Subjects
T cells, CYTOKINE release syndrome, LYMPHOMAS
Abstract

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI-CD19 CAR T CELLS IN LARGE B-CELL LYMPHOMA: A DESCAR-T REGISTRY STUDY FORM THE LYSA B Background: b Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common immune-related toxicities associated with chimeric antigen receptor (CAR)-T-cell therapy. B S. Legouill b Honoraria: Janssen-Cilag, Kite/Gilead and Novartis B G. Cartron b Honoraria: Roche, Bristol Myers Squibb, Onwards Therapeutics, MedxCell, EmerCell, MabQ, Sanofi, Abbvie, Takeda, Roche, Janssen, Roche, Novartis and Myltenyi B D. Beauvais b Honoraria: Kite/Gilead B F. Gros b Honoraria: Bristol Myers Squibb, Novartis and Kite/Gilead B P. Bories b Honoraria: Bristol Myers Squibb, Kite/Gilead, Novartis and Abbvie B M. Rubio b Honoraria: Novartis and Kite/Gilead. [Extracted from the article]

Published
2023
Full Text
View/download PDF

28. EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.

Author

Delfau‐Larue, M., Viailly, P., Cartron, G., Morschhauser, F., Gros, F., Gastinne, T., Oberic, L., Bachy, E., Dulery, R., Feugier, P., Menard, C., Quelen, C., Pangault, C., Portugues, C., Gomes, L., Itti, E., Bailly, C., Lemonnier, F., Laurent, C., and Houot, R.

Subjects
CIRCULATING tumor DNA, T cells, LYMPHOMAS
Abstract

EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY B Introduction: b CAR T-cells have significantly improved the outcome of patients with relapsed or refractory ( I R i / I R i ) large B-cell lymphoma (LBCL). The aim of our study was to monitor ctDNA before and after CAR T-cell infusion and correlate the results with clinical outcome in the ALYCANTE trial. [Extracted from the article]

Published
2023
Full Text
View/download PDF

29. Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’

Author

Fossard, G., primary, Broussais, F., additional, Coelho, I., additional, Bailly, S., additional, Nicolas-Virelizier, E., additional, Toussaint, E., additional, Lancesseur, C., additional, Le Bras, F., additional, Willems, E., additional, Tchernonog, E., additional, Chalopin, T., additional, Delarue, R., additional, Gressin, R., additional, Chauchet, A., additional, Gyan, E., additional, Cartron, G., additional, Bonnet, C., additional, Haioun, C., additional, Damaj, G., additional, Gaulard, P., additional, Fornecker, L., additional, Ghesquières, H., additional, Tournilhac, O., additional, Gomesda Silva, M., additional, Bouabdallah, R., additional, Salles, G., additional, and Bachy, E., additional

Published
2021
Full Text
View/download PDF

31. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES

Author

Gouill, S., primary, Bachy, E., additional, Blasi, R., additional, Cartron, G., additional, Beauvais, D., additional, Bras, F., additional, Gros, François‐X., additional, Choquet, S., additional, Bories, P., additional, Rubio, Marie‐Thérès., additional, Casasnovas, René‐O., additional, Bounaix, L., additional, Mohty, M., additional, Joris, M., additional, Gastinne, T., additional, Sesques, P., additional, Tudesq, J. J., additional, Morschhauser, F., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, and Houot, R., additional

Published
2021
Full Text
View/download PDF

32. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15)

Author

Maerevoet, M., primary, Casasnovas, O., additional, Cartron, G., additional, Morschhauser, F., additional, Thieblemont, C., additional, Bouabdallah, K., additional, Feugier, P., additional, Szablewski, V., additional, Becker, S., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

33. THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)

Author

Morschhauser, F., primary, Nowakowski, G. S., additional, Cartron, G., additional, Kesanakurthy, V., additional, Gkasiamis, A., additional, Patah, P., additional, Delarue, R., additional, Wang, T., additional, Li, J., additional, Xian, D., additional, Fox, C. P., additional, and Martin, P., additional

Published
2021
Full Text
View/download PDF

34. PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP

Author

Al Tabaa, Y., primary, Casasnovas, O., additional, Baillet, C., additional, Bachy, E., additional, Virelizier, E. Nicolas, additional, Schiano de Colella, J. M., additional, Bailly, C., additional, Kanoun, S., additional, Guidez, S., additional, Gyan, E., additional, Gressin, R., additional, Morineau, N., additional, Ysebaert, L., additional, Le Gouill, S., additional, Tilly, H., additional, Houot, R., additional, Morschhauser, F., additional, Cartron, G., additional, and Herbaux, C., additional

Published
2021
Full Text
View/download PDF

35. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Cartron, G., primary, Bachy, E., additional, Guidez, S., additional, Gyan, E., additional, Gressin, R., additional, Morineau, N., additional, Sibon, D., additional, Casasnovas, O., additional, Le Gouill, S., additional, Tilly, H., additional, Ysebaert, L., additional, Schiano de Colella, J. M., additional, Feugier, P., additional, Virelizier, E. Nicolas, additional, Haioun, C., additional, Damaj, G., additional, Tarte, K., additional, Laurent, C., additional, Houot, R., additional, Thieblemont, C., additional, Morschhauser, F., additional, and Herbaux, C., additional

Published
2021
Full Text
View/download PDF

36. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

Author

Bohers, E, primary, Delfau‐Larue, M, additional, Vercellino, L, additional, Cottereau, A, additional, Viennot, M, additional, Viailly, P, additional, Salles, G, additional, Tilly, H, additional, Damaj, G, additional, Haioun, C, additional, Ribrag, V, additional, Morschhauser, F, additional, Casasnovas, R, additional, Nicolas‐Virelizier, E, additional, Feugier, P, additional, Bouabdallah, R, additional, Cartron, G, additional, Renaud, L, additional, Chartier, L, additional, Portugues, C, additional, Meignan, M, additional, Jardin, F, additional, and Thieblemont, C, additional

Published
2021
Full Text
View/download PDF

38. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)

Author

Pirosa, M. C., primary, Orsucci, L., additional, Feugier, P., additional, Tani, M., additional, Ghesquieres, Hervé, additional, Musuraca, G., additional, Baldini, L., additional, Merli, F., additional, Renzis, B., additional, Gyan, E., additional, Gini, G., additional, Marino, D., additional, Gressin, R., additional, Morschhauser, F., additional, Palombi, F., additional, Cavallo, F., additional, Conconi, A., additional, Gouill, S., additional, Tilly, Hervé, additional, Zanni, M., additional, Cabras, M. G., additional, Capochiani, E., additional, Califano, C., additional, Molinari, A. L., additional, Pulsoni, A., additional, Angrilli, F., additional, Cartron, G., additional, Casasnovas, O., additional, Devizzi, L., additional, Haioun, C., additional, Houot, R., additional, Liberati, A. M., additional, Occhini, U., additional, Merli, M., additional, Pietrantuono, G., additional, Re, F., additional, Spina, M., additional, Esposito, F., additional, Bertoni, F., additional, Rossi, D., additional, Ielmini, N., additional, Luminari, S., additional, Cavalli, F., additional, Zucca, E., additional, Stathis, A., additional, and Thieblemont, C., additional

Published
2021
Full Text
View/download PDF

39. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Herbaux, C., primary, Schiano de Colella, J. M., additional, Thieblemont, C., additional, Guidez, S., additional, Ysebaert, L., additional, Tilly, H., additional, Gouill, S., additional, Houot, R., additional, Bachy, E., additional, Laurent, C., additional, Damaj, G., additional, Feugier, P., additional, Morineau, N., additional, Tarte, K., additional, Morschhauser, F., additional, and Cartron, G., additional

Published
2021
Full Text
View/download PDF

40. AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS

Author

Marouf, A., primary, Cottereau, A. S., additional, Kanoun, S., additional, Deschamps, P., additional, Franchi, P., additional, Meignan, M., additional, Sibon, D., additional, Gastinne, T., additional, Borel, C., additional, Hammoud, M., additional, Sicard, G., additional, Gille, R., additional, Cavalieri, D., additional, Stamatoullas, A., additional, Clement, L., additional, Lazarovici, J., additional, Chauchet, A., additional, Fornecker, L. M., additional, Amorin, S., additional, Rocquet, M., additional, Raus, N., additional, Burroni, B., additional, Rubio, M. T., additional, Casasnovas, O., additional, Cartron, G., additional, Bouscary, D., additional, Brice, P., additional, Ghesquieres, H., additional, Tamburini, J., additional, and Deau, B., additional

Published
2021
Full Text
View/download PDF

41. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Author

Gattermann N., Finelli C., Della Porta M., Fenaux P., Ganser A., Guerci-Bresler A., Schmid M., Taylor K., Vassilieff D., Habr D., Domokos G., Roubert B., Rose C., Agaoglu L., Alimena G., Alonso D., Ame S., Angelucci E., Arrizabalaga B., Athanasiou-Metaxa M., Augustson B., Aydinok Y., Baba A., Baccarani M., Beck J., Beris P., Beyne-Rauzy O., Birgens H., Bordessoule D., Borgna-Pignatti C., Bosly A., Bouabdallah K., Bowden D., Bowen D., Bron D., Cappellini M.D., Capra M., Cartron G., Cazzola M., Chalkias C., Chan L.L., Chancharunee S., Chapman C., Charoenkwan P., Chasapopoulou E., Cheze S., Chuansumrit A., Cianciulli P., Dauriac C., Delforge M., Dolken G., Dombret H., Duyster J., Economopoulos T., Ehninger G., Elalfy M., El-Beshlawy A., Enggaard L., Fillet G., Filosa A., Forni G., Galanello R., Gastl G., Giraudier S., Goldfarb A., Grigg A., Gumruk F., Ha S.Y., Haase D., Heinrich B., Hertzberg M., Ho J., Hsu H.-C., Huang S., Hunault-Berger M., Inusa B., Jaulmes D., Jensen J., Kattamis A., Kilinc Y., Kim K.-H., Kinsey S., Kjeldsen L., Koren A., Lai M.E., Lai Y., Lee J.-W., Lee K.-H., Lee S.-H., Legros L., Li C., Li C.-K., Li Q., Lin K.-H., Linkesch W., Lubbert M., Lutz D., Mohamed Thalha A.J., Mufti G., Muus P., Nobile F., Papadopoulos N., Perrotta S., Petrini M., Pfeilstocker M., Piga A., Poole J., Porter J.B., Pungolino E., Quarta G., Ravoet C., Jolimont Lobbes H.H., Remacha A.F., Roy L., Saglio G., Sanz G., Schmugge M., Schots H., Secchi G., Seymour J.F., Shah F., Shah H., Shen Z., Slama B., Sutcharitchan P., Taher A., Tamary H., Tesch H.-J., Thein S.L., Troncy J., Villegas A., Viprakasit V., Wainwright L., Wassmann B., Wettervald M., Will A., Wormann B., Wright J., Yeh S.-P., Yoon S.-S., Zoumbos N.C., Zweegman S., Gattermann N., Finelli C., Della Porta M., Fenaux P., Ganser A., Guerci-Bresler A., Schmid M., Taylor K., Vassilieff D., Habr D., Domokos G., Roubert B., Rose C., Agaoglu L., Alimena G., Alonso D., Ame S., Angelucci E., Arrizabalaga B., Athanasiou-Metaxa M., Augustson B., Aydinok Y., Baba A., Baccarani M., Beck J., Beris P., Beyne-Rauzy O., Birgens H., Bordessoule D., Borgna-Pignatti C., Bosly A., Bouabdallah K., Bowden D., Bowen D., Bron D., Cappellini M.D., Capra M., Cartron G., Cazzola M., Chalkias C., Chan L.L., Chancharunee S., Chapman C., Charoenkwan P., Chasapopoulou E., Cheze S., Chuansumrit A., Cianciulli P., Dauriac C., Delforge M., Dolken G., Dombret H., Duyster J., Economopoulos T., Ehninger G., Elalfy M., El-Beshlawy A., Enggaard L., Fillet G., Filosa A., Forni G., Galanello R., Gastl G., Giraudier S., Goldfarb A., Grigg A., Gumruk F., Ha S.Y., Haase D., Heinrich B., Hertzberg M., Ho J., Hsu H.-C., Huang S., Hunault-Berger M., Inusa B., Jaulmes D., Jensen J., Kattamis A., Kilinc Y., Kim K.-H., Kinsey S., Kjeldsen L., Koren A., Lai M.E., Lai Y., Lee J.-W., Lee K.-H., Lee S.-H., Legros L., Li C., Li C.-K., Li Q., Lin K.-H., Linkesch W., Lubbert M., Lutz D., Mohamed Thalha A.J., Mufti G., Muus P., Nobile F., Papadopoulos N., Perrotta S., Petrini M., Pfeilstocker M., Piga A., Poole J., Porter J.B., Pungolino E., Quarta G., Ravoet C., Jolimont Lobbes H.H., Remacha A.F., Roy L., Saglio G., Sanz G., Schmugge M., Schots H., Secchi G., Seymour J.F., Shah F., Shah H., Shen Z., Slama B., Sutcharitchan P., Taher A., Tamary H., Tesch H.-J., Thein S.L., Troncy J., Villegas A., Viprakasit V., Wainwright L., Wassmann B., Wettervald M., Will A., Wormann B., Wright J., Yeh S.-P., Yoon S.-S., Zoumbos N.C., and Zweegman S.

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ~50% were chelation-naive. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naive or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. © 2010 Elsevier Ltd.

Published
2021

42. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Author

Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Pagano L. (ORCID:0000-0001-8287-928X), and Dragonetti G.

Abstract

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. Ho

Published
2021

47. Maintien à long terme d’une réponse complète avec maladie résiduelle indétectable après une stratégie de traitement combinant de l’ibrutinib à une immunochimiothérapie ≪ adaptée ≫ chez les patients atteints d’une leucémie lymphoïde chronique non antérieurement traitée

Author

Michallet, A.S., Dilhuydy, M.S., Subtil, F., Rouille, V., Mahé, B., Laribi, K., Villemagne, B., Salles, G., Tournilhac, O., Delmer, A., Leblond, V., Tomowiak, C., FORNECKER, L.M., Letestu, R., Lévy, V., Cymbalista, F., Ysebaert, Loic, Dartigeas, C., Aurran, T., Lepretre, S., Le Garff-Tavernier, M., Ticchioni, M., Aanaei, C., Nguyen-Khac, F., Banos, A., Carassou, P., Cartron, G., Truchan-Graczyk, M., Portois, C., Pegourie, B., Feugier, P., Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), and CHADEYRON, DOMINIQUE

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Abstract

11-03; International audience

Published
2020

48. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, AP, Wu, JQ, Kipps, T, Eichhorst, B, Hillmen, P, D'Rozario, J, Assouline, S, Owen, C, Robak, T, de la Serna, J, Jaeger, U, Cartron, G, Montillo, M, Dubois, J, Eldering, E, Mellink, C, Van Der Kevie-Kersemaekers, A-M, Kim, SY, Chyla, B, Punnoose, E, Bolen, CR, Assaf, ZJ, Jiang, Y, Wang, J, Lefebure, M, Boyer, M, Humphrey, K, Seymour, JF, Kater, AP, Wu, JQ, Kipps, T, Eichhorst, B, Hillmen, P, D'Rozario, J, Assouline, S, Owen, C, Robak, T, de la Serna, J, Jaeger, U, Cartron, G, Montillo, M, Dubois, J, Eldering, E, Mellink, C, Van Der Kevie-Kersemaekers, A-M, Kim, SY, Chyla, B, Punnoose, E, Bolen, CR, Assaf, ZJ, Jiang, Y, Wang, J, Lefebure, M, Boyer, M, Humphrey, K, and Seymour, JF

Abstract

PURPOSE: In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics. PATIENTS AND METHODS: Patients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed. RESULTS: Of 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT. CONCLUSION: Efficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results